Core Viewpoint - The company has approved a proposal to utilize part of its idle raised funds for cash management, aiming to enhance the efficiency of fund usage and increase returns on cash assets [1] Group 1: Cash Management Proposal - The company plans to use no more than 500 million yuan of temporarily idle raised funds for cash management [1] - The funds will be invested in high-security, liquid principal-protected products, including but not limited to structured deposits, time deposits, large certificates of deposit, notice deposits, and principal-protected income certificates [1] - The investment period for individual products will not exceed 12 months, and the usage period is valid for 12 months from the date of board approval [1] Group 2: Impact on Company Operations - This cash management initiative will not affect the normal progress of the company's fundraising projects [1] - The objective is to improve the efficiency of the raised funds and increase returns on cash assets [1]

Core Viewpoint - Shandong Weigao Orthopedic Materials Co., Ltd. announced plans to use part of its idle funds for cash management, aiming to enhance fund efficiency and returns while ensuring normal operations and fund safety [1][2]. Cash Management Overview - Investment Purpose: To improve fund efficiency and returns while safeguarding normal operations and fund safety, ultimately benefiting shareholders [2]. - Investment Products: The company plans to invest in high-security, liquid financial products with capital protection agreements, such as principal-protected wealth management products, structured deposits, and fixed-term deposits [2]. - Decision Validity: The resolution is valid for 12 months from the date of board approval, with a maximum investment of RMB 2.3 billion [2]. - Implementation: The board authorizes the chairman and management to make investment decisions within the approved limits and timeframe [2]. - Information Disclosure: The company will comply with legal requirements for timely information disclosure [2]. Risk Management and Control - The company has implemented several risk control measures, including selecting reputable financial institutions, real-time monitoring of product performance, and prohibiting personal account operations [3]. - Internal audits will evaluate investment risks and returns, with oversight from independent directors and the supervisory board [3]. Impact on the Company - The cash management initiative will not affect the company's main business operations or shareholder interests, and is expected to enhance fund efficiency and returns [4]. - Both the board and supervisory board have expressed clear agreement on the cash management plan, deeming it compliant with relevant requirements [4].

Core Viewpoint - The company intends to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency and returns while ensuring that it does not affect the construction of investment projects or the normal operations of the company [1][10]. Fundraising Basic Situation - The company was approved to publicly issue 20.5 million shares at a price of RMB 37.85 per share, raising a total of RMB 701.33 million, which was fully received by November 2, 2022 [1][2]. Investment Project Situation - The total investment amount for the projects funded by the raised funds is RMB 412.42 million, with the company experiencing temporary idle funds due to the construction cycle of these projects [3][4]. Previous Authorization for Cash Management - The company’s board approved the use of up to RMB 670 million of temporarily idle funds for cash management on December 3, 2022, allowing for investments in high-security, liquid financial products [5][6]. Current Cash Management Usage - The company plans to use up to RMB 500 million of temporarily idle funds for cash management, with a focus on safe and liquid investment products, ensuring that these funds are not used for pledging or securities investment [6][7]. Investment Purpose and Products - The purpose of using idle funds is to improve efficiency and returns without impacting project construction or fund safety. The investment products include guaranteed principal financial products, structured deposits, and large certificates of deposit [6][8]. Investment Limits and Duration - The company will use a maximum of RMB 500 million for cash management, with a validity period of 12 months from the board's approval date, allowing for rolling use of the funds within this limit [6][9]. Impact on Daily Operations - The cash management of idle funds will not affect the ongoing investment projects or the company's main business, and it aims to enhance fund efficiency and returns for shareholders [7][9]. Supervisory and Sponsor Opinions - The supervisory board agrees that the cash management plan complies with relevant regulations and will not harm the interests of shareholders, while the sponsor confirms that the necessary approval procedures have been followed [9][10].

Group 1 - The company, Medisi, announced on August 8 that it will hold the fifth meeting of the fourth board of directors and the fifth meeting of the fourth supervisory board on August 8, 2025 [2] - The company approved a proposal to use part of the temporarily idle raised funds for cash management, with a maximum amount of RMB 400 million [2] - The funds will be used to purchase investment products with high safety and liquidity, including but not limited to guaranteed wealth management products, guaranteed income certificates, structured deposits, time deposits, notice deposits, and large-denomination certificates of deposit [2] - The usage period for these funds is within 12 months from the approval of the board meeting, allowing for rolling use within the specified limit and validity period of the resolution [2]

Summary of Key Points Core Viewpoint - The company, Shanghai Medicy Bio-pharmaceutical Co., Ltd., is utilizing part of its idle raised funds for cash management to enhance fund efficiency and generate additional income while ensuring the safety of the funds and not affecting the ongoing investment projects [1][8]. Group 1: Fundraising Overview - The total amount raised by the company as of August 4, 2023, is RMB 1 billion, with a net amount of RMB 985.29 million after deducting underwriting fees [1]. - The funds are stored in a special account, and a tripartite agreement has been signed to regulate the management of these funds [2]. Group 2: Investment Project Details - The net amount raised will be allocated to specific projects, including the establishment of a biopharmaceutical innovation industrial base and laboratory expansion for drug discovery and pharmaceutical research [2]. - The total planned investment for these projects is RMB 2.176 billion, with the adjusted amount from the raised funds being RMB 216 million [2]. Group 3: Cash Management Strategy - The company plans to use up to RMB 400 million of the temporarily idle funds for cash management, ensuring that this does not impact the ongoing projects [4][7]. - The cash management products will include safe and liquid investments such as principal-protected wealth management products, structured deposits, and time deposits [4][6]. Group 4: Decision-Making and Oversight - The board of directors has authorized the management to make investment decisions within the set limits and timeframes, with the finance department responsible for implementation [4][6]. - The company will adhere to disclosure obligations and ensure that the cash management does not alter the intended use of the raised funds [5][8]. Group 5: Monitoring and Compliance - The supervisory board supports the cash management initiative, stating it aligns with regulations and benefits the company and shareholders [7]. - The sponsor institution has confirmed that the cash management plan complies with relevant regulations and does not affect the normal execution of investment projects [8].